What You Should Know:
– Owlet, a provider of smart infant monitoring technology, announced a strategic partnership with Wheel, a prominent virtual healthcare provider.
– The partnership empowers Wheel’s network of clinicians to prescribe Owlet’s BabySat, an FDA-cleared infant pulse oximeter. This innovative device, featuring a comfortable sock design, allows caregivers to effectively monitor their baby’s health vitals at home. This collaboration fosters closer collaboration between parents and healthcare providers, ensuring optimal newborn care.
Addressing Critical Needs
Each year, over 450,000 babies transition home from neonatal intensive care units (NICUs) in the US alone. Additionally, congenital heart disease (CHD) affects 40,000 newborns annually, and an estimated 58,000-80,000 children under five require hospitalization due to respiratory syncytial virus (RSV).
Streamlined Access and Reimbursement
The BabySat virtual telehealth platform, powered by Wheel, simplifies access to this vital monitoring tool. The platform integrates with durable medical equipment (DME) suppliers, facilitating insurance billing and potentially offering up to 100% reimbursement for BabySat. This streamlined process significantly reduces the time and effort required for families to secure the device and receive insurance or HSA/FSA reimbursement.
“We’re thrilled to announce our strategic partnership with Owlet, a leader in smart infant monitoring. This collaboration marks a significant milestone in our mission to expand healthcare access and simplify care delivery for all Americans — especially for growing families,” said Wheel CEO, Michelle Davey. “Wheel’s virtual care platform helps streamline access to home monitoring, making Owlet’s BabySat pulse oximeter more convenient for new parents than ever before.
